CarsonAllaria Wealth Management’s Day One Biopharmaceuticals DAWN Stock Holding History

CarsonAllaria Wealth Management’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-180	Closed	-$2.48K	–	400
2024 Q2	$2.48K	Hold	180	–	–	﹤0.01%	316
2024 Q1	$2.97K	Sell	180 -250	-58%	-$3.74K	﹤0.01%	318
2023 Q4	$6.28K	Hold	430	–	–	﹤0.01%	247
2023 Q3	$5.28K	Buy	430 +330	+330%	+$4.3K	﹤0.01%	255
2023 Q2	$1.19K	Buy	+100	New	+$1.31K	﹤0.01%	347

Other funds holding DAWN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CarsonAllaria Wealth Management's DAWN Position: Q3 2024 in Review

CarsonAllaria Wealth Management sold out of Day One Biopharmaceuticals (DAWN) in Q3 2024, closing a stake of 180 shares — an estimated $2.48K sold.

CarsonAllaria Wealth Management first reported a position in DAWN in Q2 2023 and held it in 5 quarters. The position peaked at $6.28K in Q4 2023. 166 funds tracked by Wall St. Rank hold DAWN as of Q3 2024.

CarsonAllaria Wealth Management reported no remaining Day One Biopharmaceuticals position as of Q3 2024 after selling out during the quarter.
CarsonAllaria Wealth Management sold 180 Day One Biopharmaceuticals shares in Q3 2024, an estimated $2.48K.
CarsonAllaria Wealth Management first reported a position in Day One Biopharmaceuticals in Q2 2023 and held it in 5 quarters.
CarsonAllaria Wealth Management's Day One Biopharmaceuticals position peaked at $6.28K in Q4 2023.
166 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q3 2024.

Based on CarsonAllaria Wealth Management's 13F filing for Q3 2024, filed 21 Oct 2024.